Lim Sung-ki, founder and chairman of Hanmi Pharmaceutical, one of Korea’s top drugmakers, passed away on the early morning of Aug. 2 at the age of 80 from chronic illness.
Exports of medical products, such as medicine, medical devices and cosmetics, increased by nearly 27 percent during the first half of this year.
Celltrion is so confident that it will receive approval to run a Phase 3 trial on its Covid-19 treatment that it is manufacturing enough of the material ahead of time for the trial and for commercial distribution afterwards.
Celltrion received approval for Phase 1 clinical trials for a Covid-19 treatment candidate, the Ministry of Food and Drug Safety announced Friday.
The U.S. International Trade Commission (ITC) made an initial determination Monday. It concluded that Daewoong’s botulinum toxin product, Nabota, was made with bacteria and intellectual property stolen from Medytox.
Remdesivir, the antiviral drug from Gilead Sciences that may be effective in the treatment of Covid-19, will be available to Korean hospitals starting today, said the Korea Centers for Disease Control and Prevention (KCDC).
Over the following months Korea’s bio industry has been rushing to develop treatments and vaccines for the virus. Despite the hype, Korean companies are still in the very early stages of developing treatments.
Samsung BioLogics announced Friday that it has signed a contract manufacturing organization deal worth more than 283.9 billion won ($229 million) with British pharmaceutical company GlaxoSmithKline (GSK).
Paris-based Sanofi is seeking an exit from a deal with Hanmi Pharmaceutical involving global marketing rights to efpeglenatide, a diabetes drug. Shares of Kospi-listed Hanmi fell almost 10 percent on the news.
Chong Kun Dang has entered the Korean botulinum toxin market this month. The local biopharmaceutical company announced Friday it is launching Wondertox to enter the local botulinum toxin market worth around 100 billion won ($81.6 million).